HIV Immunotherapy

Clinical Trial Findings Show Remune Has "Significant Effect" On Viral Load

Published in AIDS Weekly, August 13th, 2001

New virological findings from the Phase II clinical trial (STIR 2102) completed in Spain with Remune^TM (HIV-1 Immunogen), an investigational immune-based therapy of the Immune Response Corp. (IMNR), were reported at the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment in Buenos Aires, Argentina.

Principal investigator Prof. Eduardo Fernandez-Cruz, MD, PhD, head of the Department of Clinical Immunology at the University General Hospital "Gregorio Maranon" in Madrid, Spain, his colleagues analyzed the data, along with Immune Response Corp., and three outside consultants engaged by the company to independently review the data using the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2001-08-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry